SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Caribou Biosciences, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 02/16/23
CARIBOU BIOSCIENCES, INC. (CRBU) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces That a Securities Class Action Lawsuit Has Been Filed Against Caribou Biosciences, Inc. (CRBU)Newsfile Corp • 02/15/23
Caribou Class Action: Levi & Korsinsky Reminds Caribou Biosciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 11, 2023 - CRBUNewsfile Corp • 02/15/23
CARIBOU BIOSCIENCES, INC. (NASDAQ: CRBU) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Caribou Biosciences, Inc. (NASDAQ: CRBU)PRNewsWire • 02/15/23
CARIBOU ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Caribou Biosciences, Inc. and Encourages Investors to Contact the FirmBusiness Wire • 02/15/23
CRBU INVESTOR NOTICE: ROSEN, A LEADING NATIONAL FIRM, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBUPRNewsWire • 02/15/23
INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Caribou Biosciences, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 02/14/23
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Caribou Biosciences, Inc. (CRBU)Business Wire • 02/14/23
SHAREHOLDER ALERT: Class Action Lawsuit Filed on Behalf of Caribou Biosciences, Inc. (CRBU) Investors - Nationally Ranked Investors' Rights Firm Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the FirmNewsfile Corp • 02/13/23
CRBU INVESTOR ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CRBUBusiness Wire • 02/13/23
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Caribou Biosciences, Inc. with Losses of $100,000 to Contact the FirmBusiness Wire • 02/13/23
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Caribou Biosciences, Inc. with Losses of $100,000 to Contact the FirmBusiness Wire • 02/12/23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Caribou Biosciences, Inc. - CRBUNewsfile Corp • 02/10/23
Caribou Biosciences to Present at 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/03/23
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Caribou Biosciences, Inc. and Encourages Investors with Losses to Contact the FirmBusiness Wire • 12/28/22
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Caribou Biosciences, Inc. and Encourages Investors with Losses to Contact the FirmBusiness Wire • 12/27/22
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Caribou Biosciences, Inc. and Encourages Investors with Losses to Contact the FirmNewsfile Corp • 12/26/22
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Caribou Biosciences, Inc. and Encourages Investors with Losses to Contact the FirmNewsfile Corp • 12/23/22
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Caribou Biosciences, Inc. and Encourages Investors with Losses to Contact the FirmNewsfile Corp • 12/22/22
INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Caribou Biosciences, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 12/21/22
Caribou Biosciences Selects ROR1 as the Target for CB-020, an iPSC-derived Allogeneic CAR-NK Cell TherapyGlobeNewsWire • 12/12/22
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations to CB-010, an Allogeneic Anti-CD19 CAR-T Cell TherapyGlobeNewsWire • 11/29/22
Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple MyelomaGlobeNewsWire • 11/21/22
